27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
- Pfizer Inc (NYSE:PFE) has initiated a Phase 3 clinical trial evaluating its respiratory syncytial virus (RSV) bivalent prefusion F subunit investigational vaccine candidate (RSVpreF) in adults ages 60 years or older.
- The Phase 3 RENOIR trial will enroll approximately 30,000 participants 60 years and older.
- The study's primary objectives will assess safety and efficacy for preventing moderate to severe lower respiratory tract illness (msLRTI-RSV) during the first RSV season.
- Related Content: Moderna RSV-Targeted mRNA Vaccine Candidate Gets Fast Track Tag In US
- Price Action: PFE stock is up 0.53% at $46.29 during the premarket session on the last check Thursday.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!